Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral hypoglycemic agent update

L P Krall, V A Chabot

    The Medical Clinics of North America
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Oral hypoglycemic agents offer a public health advance for diabetes management, simplifying care but with limitations. Sulfonylureas are effective for some maturity-onset diabetics when used appropriately, though diet and insulin remain crucial for severe cases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diabetes in a New England town; a study of 3,516 persons in Oxford, Mass.

    Journal of the American Medical Association·2010
    Same author

    The history of diabetes lay associations.

    Patient education and counseling·1995
    Same author

    [Gestational diabetes].

    Schweizerische medizinische Wochenschrift. Supplementum·1994
    Same author

    The gliclazide poster world in Lisbon, 1989.

    The American journal of medicine·1991
    Same author

    The treatment of NIDDM in the decade of the 90s.

    Diabetes research and clinical practice·1991
    Same author

    Wide, wide world of diabetes mellitus.

    The Diabetes educator·1986
    Same journal

    Care Transitions Continue to Evolve.

    The Medical clinics of North America·2026
    Same journal

    Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

    The Medical clinics of North America·2026
    Same journal

    Care Transitions and Value-Based Payment Models in the United States.

    The Medical clinics of North America·2026
    Same journal

    Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

    The Medical clinics of North America·2026
    Same journal

    Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

    The Medical clinics of North America·2026
    Same journal

    Social Determinants of Health: Unique Considerations in Transitions of Care.

    The Medical clinics of North America·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Pharmacology
    • Public Health

    Background:

    • Diabetes mellitus treatment remains a challenge over 50 years post-insulin discovery.
    • Traditional treatments included exercise, diet, and insulin; oral hypoglycemic agents emerged as a significant advancement.
    • Establishing therapeutic goals is essential for evaluating treatment effectiveness, with evidence suggesting normal blood glucose is desirable but severe hypoglycemia must be avoided.

    Purpose of the Study:

    • To review the role and effectiveness of oral hypoglycemic agents in diabetes management.
    • To discuss the indications, contraindications, and limitations of currently available oral agents, primarily sulfonylureas.
    • To compare the utility of oral agents with diet and insulin therapy for different diabetes patient populations.

    Main Methods:

    Related Experiment Videos

    • Literature review and analysis of historical and current treatment modalities for diabetes.
    • Examination of the pharmacological properties and clinical applications of sulfonylureas.
    • Discussion of patient selection criteria and potential adverse effects associated with oral hypoglycemic agents.

    Main Results:

    • Oral agents, particularly sulfonylureas, offer a less intimidating treatment option than insulin for many early-stage diabetes patients.
    • Sulfonylureas require a functional beta-cell system and are generally indicated for maturity-onset diabetes over 40 with less than 10 years of disease.
    • These agents can effectively lower blood glucose in properly selected patients but have limitations, including temporary efficacy and contraindications in certain conditions like juvenile-onset diabetes or pregnancy.

    Conclusions:

    • Oral hypoglycemic agents represent a valuable public health advance, simplifying diabetes care for many.
    • Despite some skepticism, oral agents can be effective when used appropriately in selected patients, though they are not universally effective and have limitations.
    • Diet therapy remains a primary treatment choice for many, while insulin is essential for severe diabetes; oral agents serve a specific niche in the treatment spectrum.